Neurocrine Biosciences | NBIX - Процентные расходы





Процентные расходы Изменить Дата
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
ALKERMES USD 25.92M 5.03M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Cytokinetics USD 34.83M 1.5M 2026-06
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 247M 7M 2026-06
Halozyme Therapeutics USD 5.59M 80K 2026-06
Incyte USD 582K 13K 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 667M 4M 2026-06
Prothena USD 302.58M 47.32M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Repligen USD 5.66M 85K 2026-06
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sarepta Therapeutics USD 21.51M 205K 2026-06
Teva Pharmaceutical Industries USD 195M 21M 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12